VDAC1-Based Peptides as Potential Modulators of VDAC1 Interactions with Its Partners and as a Therapeutic for Cancer, NASH, and Diabetes. This evidence concerns the gene VDAC1 and metabolic dysfunction-associated steatohepatitis.